Global Cardiovascular Drugs Market Outlook, 2031

The global cardiovascular drugs industry covers medicines used to prevent and treat diseases of the heart and blood vessels, including hypertension, dyslipidaemia, coronary artery disease, heart failure, atrial fibrillation, thrombosis, stroke prevention, pulmonary arterial hypertension, cardiomyopathies and peripheral artery disease. Cardiovascular disease remains the leading cause of death worldwide, responsible for about 20 million deaths a year according to the World Heart Federation. The market includes very large volumes of low-cost generics, such as statins, ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, diuretics and aspirin, alongside high-value branded products. Leading branded drugs include Bristol Myers Squibb and Pfizer's Eliquis and Bayer and Johnson & Johnson's Xarelto for anticoagulation, Novartis's Entresto for heart failure, AstraZeneca's Farxiga and Boehringer Ingelheim and Lilly's Jardiance, SGLT2 inhibitors widely used in heart failure and chronic kidney disease, Amgen's Repatha, Regeneron and Sanofi's Praluent and Novartis's Leqvio for LDL cholesterol lowering, Pfizer's Vyndaqel and BridgeBio's Attruby for transthyretin amyloid cardiomyopathy, Merck's Winrevair for pulmonary arterial hypertension, and Bristol Myers Squibb's Camzyos and Cytokinetics' Myqorzo for obstructive hypertrophic cardiomyopathy. GLP-1 drugs such as Novo Nordisk's Wegovy have also gained cardiovascular indications. The cardiovascular market has shifted from a mature, genericised field to one with significant innovation. SGLT2 inhibitors, originally developed for diabetes, became foundational heart failure treatments after trials between 2019 and 2022, and in March 2024 the FDA approved Wegovy to reduce cardiovascular events in overweight patients with heart disease based on the SELECT trial, opening a large new use for obesity drugs. Precision cardiology has advanced with treatments for specific conditions, including cardiac myosin inhibitors for hypertrophic cardiomyopathy, transthyretin stabilisers and silencers for amyloid cardiomyopathy and activin signalling inhibitors for pulmonary arterial hypertension. Lipid lowering is entering a new phase: in July 2026 the FDA approved Merck's enlicitide, marketed as Lipfendra, the first oral PCSK9 inhibitor, and several companies are testing drugs that lower lipoprotein(a), a genetic risk factor. In hypertension, the FDA approved AstraZeneca's baxdrostat, an aldosterone synthase inhibitor, in May 2026 for hard-to-control blood pressure. Pricing pressure has increased at the same time. Under the US Inflation Reduction Act, Medicare's first negotiated prices, covering Eliquis, Xarelto, Entresto, Jardiance and Farxiga among others, took effect on 1 January 2026, and generic versions of Entresto entered the US market in 2025, while Eliquis and Xarelto face generic competition in several countries. Market Dynamics Market Drivers • High and Rising Burden of Cardiovascular DiseaseAgeing populations, obesity, diabetes, sedentary lifestyles and high salt diets are increasing the prevalence of hypertension, heart failure, atrial fibrillation and coronary disease worldwide. Hypertension alone affects more than a billion adults, and many remain undiagnosed or poorly controlled. Heart failure is a leading cause of hospitalisation among older adults, and atrial fibrillation is growing with age. These trends ensure large and growing demand for preventive and therapeutic cardiovascular drugs. • New Mechanisms and Expanded IndicationsRecent approvals have created new treatment categories, including cardiac myosin inhibitors, transthyretin amyloid therapies, activin signalling inhibitors, aldosterone synthase inhibitors and oral PCSK9 inhibitors. Established drugs, including SGLT2 inhibitors and GLP-1 receptor agonists, have gained cardiovascular and kidney indications based on outcome trials. Better diagnosis of conditions such as amyloid cardiomyopathy and hypertrophic cardiomyopathy, supported by imaging and genetic testing, has increased the number of treated patients. Market Challenges • Generic Erosion and Price RegulationMany of the largest cardiovascular brands face patent expiry during the forecast period, including Eliquis and Xarelto in major markets, and generic Entresto launched in the United States in 2025. Medicare price negotiation under the Inflation Reduction Act lowered prices for several cardiovascular drugs from 2026, and more are likely to be selected. European reference pricing and China's volume-based procurement have sharply cut prices for cardiovascular generics, putting pressure on revenues. • Poor Adherence and UndertreatmentMany patients with hypertension, high cholesterol and heart failure do not take medicines as prescribed or are never started on recommended therapy. Guideline-directed medical therapy for heart failure, which includes four drug classes, is often incompletely used. Undertreatment of LDL cholesterol with statins and PCSK9 drugs is common. These gaps reduce the benefits of existing medicines and limit market growth for newer therapies. Market Trends • Oral and Long-Acting Lipid-Lowering TherapiesLDL cholesterol lowering is moving beyond statins and injectable PCSK9 antibodies. Oral PCSK9 inhibitors, including Merck's enlicitide, approved in 2026, and AstraZeneca's AZD0780, and twice-yearly injections such as inclisiran make intensive lowering easier. CETP inhibitors such as obicetrapib, and therapies targeting lipoprotein(a), including pelacarsen, olpasiran and lepodisiran, could create new treatment segments if outcome trials are positive. Gene-editing approaches aim for one-time LDL lowering. • Convergence of Cardiology and Metabolic MedicineObesity, diabetes, kidney disease and heart disease are increasingly treated together. GLP-1 receptor agonists and dual agonists reduce cardiovascular events and heart failure symptoms, SGLT2 inhibitors protect both heart and kidneys, and finerenone treats patients with diabetic kidney disease and heart failure. Cardiologists are prescribing metabolic drugs more often, and combination strategies addressing weight, blood pressure, lipids and glucose together are becoming standard. Segment Analysis Antihypertensives and lipid-lowering drugs account for the largest volume of cardiovascular prescriptions, while anticoagulants and heart failure drugs have generated the largest branded revenues. Antihypertensive drugs, including ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics and beta-blockers, are the most widely prescribed cardiovascular medicines, mostly as low-cost generics and increasingly as single-pill combinations. New agents, such as aprocitentan, approved in 2024, and baxdrostat, approved in 2026, target resistant hypertension. Lipid-lowering drugs include statins, such as atorvastatin and rosuvastatin, used by hundreds of millions of people, ezetimibe, bempedoic acid, injectable PCSK9 antibodies, inclisiran and the oral PCSK9 inhibitor enlicitide. Anticoagulants, led by apixaban and rivaroxaban, prevent stroke in atrial fibrillation and treat venous thromboembolism, and they have been among the best-selling drugs in the world, while factor XI inhibitors such as abelacimab and asundexian are in late-stage development. Antiplatelet drugs, including aspirin, clopidogrel and ticagrelor, prevent heart attacks and stent thrombosis. Heart failure drugs include sacubitril-valsartan, SGLT2 inhibitors, mineralocorticoid receptor antagonists and vericiguat. Antiarrhythmic drugs treat atrial fibrillation and other rhythm disorders. Specialty cardiovascular drugs, including treatments for transthyretin amyloid cardiomyopathy, hypertrophic cardiomyopathy and pulmonary arterial hypertension, are high-priced therapies for smaller populations and among the fastest-growing segments. Hypertension and dyslipidaemia represent the largest patient populations, while heart failure, atrial fibrillation and rare cardiomyopathies are among the highest-value indications. Hypertension affects more than a billion people globally and is the leading modifiable risk factor for heart disease and stroke, and control rates remain low in many countries. Dyslipidaemia, especially elevated LDL cholesterol, affects a large share of adults and is treated to prevent heart attacks and strokes, with guidelines recommending increasingly low LDL targets for high-risk patients. Coronary artery disease, including stable angina and acute coronary syndromes, requires antiplatelet, lipid-lowering and anti-anginal drugs. Heart failure affects more than 60 million people worldwide, and treatment with four classes of guideline-directed drugs has improved survival, making it one of the most valuable indications. Atrial fibrillation, the most common heart rhythm disorder, requires anticoagulation to prevent stroke and rate or rhythm control drugs. Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, is treated with anticoagulants. Pulmonary arterial hypertension is a rare but high-value indication, transformed by sotatercept. Transthyretin amyloid cardiomyopathy, once considered rare, is increasingly diagnosed and treated with tafamidis, acoramidis and vutrisiran. Hypertrophic cardiomyopathy is treated with cardiac myosin inhibitors. Peripheral artery disease and stroke prevention form additional indications. Oral tablets account for the vast majority of cardiovascular drug use, while injectable therapies are growing in lipid lowering, pulmonary arterial hypertension and cardiometabolic disease. Oral tablets and capsules are the standard route for almost all cardiovascular drugs, including antihypertensives, statins, anticoagulants, antiplatelets, heart failure drugs and antiarrhythmics, and fixed-dose combinations help improve adherence. The polypill, combining several preventive drugs in one tablet, has been tested in trials and is available in some countries. Injectable therapies have grown in importance, including subcutaneous PCSK9 antibodies given every two to four weeks, inclisiran given twice a year after initial doses, sotatercept given every three weeks for pulmonary arterial hypertension, vutrisiran given every three months for amyloid cardiomyopathy, and weekly GLP-1 injections that reduce cardiovascular risk. Intravenous drugs are used in hospitals for acute conditions, including heparin, thrombolytics, antiarrhythmics and inotropes for acute heart failure. Inhaled treatments, such as inhaled treprostinil, are used in pulmonary hypertension. Transdermal patches deliver nitroglycerin and clonidine. The move toward infrequent injections, including twice-yearly siRNA therapies for cholesterol and potentially for hypertension with zilebesiran, could change adherence patterns in prevention. Retail pharmacies dispense the largest share of cardiovascular drugs, while hospital and specialty pharmacies handle acute therapies and high-cost specialty medicines. Retail pharmacies dispense most cardiovascular prescriptions, including generic antihypertensives, statins, anticoagulants and heart failure drugs, which are typically taken for many years and refilled monthly or quarterly. Hospital pharmacies supply intravenous and acute cardiovascular medicines, including anticoagulants, thrombolytics and antiarrhythmics, and they initiate many patients on long-term therapy after heart attacks or heart failure admissions. Specialty pharmacies manage high-cost products such as sotatercept, tafamidis, acoramidis, mavacamten and injectable lipid-lowering drugs, which require prior authorisation, patient support and, for cardiac myosin inhibitors, safety monitoring programmes. Online and mail-order pharmacies are widely used for chronic cardiovascular medications, particularly in the United States, where pharmacy benefit managers encourage 90-day mail supplies, and telehealth services manage hypertension and cholesterol. Direct-to-consumer channels have grown, including manufacturer programmes and discount platforms. Government procurement plays a large role in China, where volume-based procurement has cut prices for cardiovascular generics, and in national health systems in Europe. Primary care clinics and community health centres prescribe most preventive therapies. Regional Analysis North America leads the cardiovascular drugs market by value because of high prices for branded therapies, broad use of anticoagulants and specialty cardiology drugs, and early adoption of new treatments, while Asia-Pacific has the largest patient population and fastest volume growth. North America, led by the United States, generates the largest share of cardiovascular drug revenue. Branded anticoagulants, heart failure drugs, SGLT2 inhibitors, PCSK9 therapies and specialty treatments for amyloid cardiomyopathy, hypertrophic cardiomyopathy and pulmonary arterial hypertension are widely used, and the FDA approved several new cardiovascular drugs between 2024 and 2026, including Attruby, Winrevair, Myqorzo, baxdrostat and enlicitide. Medicare price negotiation, which cut prices for Eliquis, Xarelto, Entresto, Jardiance and Farxiga from January 2026, and generic Entresto are reducing revenue from older brands. Europe is the second largest market by value, with strong use of anticoagulants and heart failure therapies, but lower prices due to health technology assessment and reference pricing, and generic apixaban and rivaroxaban have entered several European countries. Asia-Pacific has the largest number of patients with hypertension and cardiovascular disease and is the fastest-growing region by volume. China has a large cardiovascular market dominated by generics after volume-based procurement, while Japan has high use of branded anticoagulants and heart failure drugs. India has a very large and growing cardiovascular patient population served mainly by domestic generic manufacturers, and has seen the launch of generic sacubitril-valsartan and other therapies. Latin America, the Middle East and Africa have rising cardiovascular disease burdens linked to urbanisation, diabetes and obesity, with treatment relying mainly on generics. Key Developments July 2026: The FDA approved Merck's enlicitide (Lipfendra) to lower LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. May 2026: AstraZeneca's aldosterone synthase inhibitor baxdrostat was approved as an add-on treatment for adults whose hypertension is inadequately controlled with other drugs. January 2026: The first Medicare negotiated prices under the Inflation Reduction Act took effect, lowering prices for cardiovascular drugs including Eliquis, Xarelto, Entresto, Jardiance and Farxiga. December 2025: Cytokinetics' cardiac myosin inhibitor aficamten was approved for symptomatic obstructive hypertrophic cardiomyopathy, becoming the second drug in its class. November 2024: BridgeBio's acoramidis was approved to treat transthyretin amyloid cardiomyopathy, expanding treatment options for a condition increasingly recognised as a cause of heart failure. March 2024: Semaglutide became the first obesity medicine approved to reduce the risk of heart attack, stroke and cardiovascular death in adults with heart disease and overweight or obesity. Considered in this report • Historic Year: 2020 • Base Year: 2025 • Estimated Year: 2026 • Forecast Year: 2031 Aspects covered in this report • Global Cardiovascular Drugs Market with its value and forecast along with its segments • Various drivers and challenges • Ongoing trends and developments • Top profiled companies • Strategic recommendation By Drug Class • Antihypertensives • Lipid-Lowering Drugs • Anticoagulants • Antiplatelet Drugs • Heart Failure Drugs • Antiarrhythmic Drugs • Specialty Cardiovascular Drugs By Indication • Hypertension • Dyslipidaemia • Coronary Artery Disease • Heart Failure • Atrial Fibrillation • Pulmonary Arterial Hypertension • Cardiomyopathies By Route of Administration • Oral • Injectable • Intravenous • Other By Distribution Channel • Retail Pharmacies • Hospital Pharmacies • Specialty Pharmacies • Online Pharmacies

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now